Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals' Board recommended a final dividend of Rs. 2.5 per equity share (250% on face value of Re. 1) for FY 2025-26, subject to shareholder approval at the AGM. On a consolidated basis, revenue from operations grew to Rs. 1,67,114 million (up 27% from Rs. 1,31,458 million), with net profit after tax rising to Rs. 13,620 million from Rs. 10,471 million, and EPS improving to Rs. 48.26 from Rs. 37.11. However, standalone results showed a net loss of Rs. 2,008 million compared to a profit of Rs. 16,104 million in the prior year, due to significant exceptional items including antitrust settlements of Rs. 6,013 million, inventory provisions of Rs. 5,901 million, and PPE impairment of Rs. 2,279 million totaling over Rs. 22,660 million in exceptional charges on consolidated basis.
The company continues to reward shareholders with dividend despite heavy exceptional charges related to US litigation settlements and inventory/property impairments. The stock may see mixed reaction given the large one-time charges impacting standalone profitability, though the consolidated business shows improved performance.